Eli Lilly and Company (NYSE:LLY) Stock Gets Price Target Increase from Morgan Stanley

Eli Lilly and Company (NYSE:LLY) had its target price upped by equities research analysts at Morgan Stanley from $1,430.00 to $1,596.00 in a note issued to investors on Friday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Morgan Stanley‘s price target suggests a potential upside of 11.91% from the company’s previous close.

Other equities research analysts have also issued research reports about the stock. Berenberg Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 price objective for the company in a report on Tuesday, September 15th. Leerink Partners boosted their target price on shares of Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the company an “outperform” rating in a report on Wednesday, October 21st. The Goldman Sachs Group reissued a “buy” rating and issued a $1,413.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, October 20th. JPMorgan Chase & Co. raised their price target on shares of Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the stock an “overweight” rating in a report on Monday, September 28th. Finally, Royal Bank Of Canada upped their price objective on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company an “outperform” rating in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus price target of $1,380.39.

Eli Lilly and Company Price Performance

Shares of LLY stock traded up $52.43 on Friday, reaching $1,426.13. 2,790,212 shares of the company were exchanged, compared to its average volume of 2,931,820. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. Eli Lilly and Company has a 1 year low of $834.19 and a 1 year high of $1,449.68. The company has a market cap of $1.34 trillion, a price-to-earnings ratio of 47.78, a P/E/G ratio of 1.73 and a beta of 0.46. The business has a 50-day moving average price of $1,194.34 and a 200 day moving average price of $1,090.89.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, beating analysts’ consensus estimates of $5.68 by $1.80. The company had revenue of $24.40 billion for the quarter, compared to analyst estimates of $22.58 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The firm’s revenue for the quarter was up 38.6% on a year-over-year basis. During the same quarter last year, the firm posted $7.02 EPS. Equities research analysts forecast that Eli Lilly and Company will post 33.22 earnings per share for the current fiscal year.

Insider Activity

In related news, CAO Donald Zakrowski sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the sale, the chief accounting officer directly owned 1,526 shares in the company, valued at approximately $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the sale, the executive vice president directly owned 11,875 shares of the company’s stock, valued at $14,131,250. This trade represents a 29.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 13,500 shares of company stock worth $15,958,170. 0.14% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Eli Lilly and Company

Several large investors have recently modified their holdings of the stock. Coastal Bridge Advisors LLC purchased a new stake in shares of Eli Lilly and Company in the second quarter valued at about $2,959,000. Mosaic Family Wealth Partners LLC increased its stake in shares of Eli Lilly and Company by 70.6% during the 2nd quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company’s stock worth $4,144,000 after purchasing an additional 1,430 shares in the last quarter. Moran Wealth Management LLC increased its stake in shares of Eli Lilly and Company by 85.6% during the 2nd quarter. Moran Wealth Management LLC now owns 20,903 shares of the company’s stock worth $25,072,000 after purchasing an additional 9,638 shares in the last quarter. Generali Investments Management Co LLC raised its position in shares of Eli Lilly and Company by 17.5% during the 2nd quarter. Generali Investments Management Co LLC now owns 10,220 shares of the company’s stock worth $12,258,000 after purchasing an additional 1,521 shares during the last quarter. Finally, Capital Investment Advisors LLC raised its position in shares of Eli Lilly and Company by 51.3% during the 3rd quarter. Capital Investment Advisors LLC now owns 44,851 shares of the company’s stock worth $51,896,000 after purchasing an additional 15,214 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong Q3 results: Lilly reported revenue of $24.4 billion, up approximately 39% year over year, while adjusted EPS of $7.48 substantially exceeded analyst expectations. Lilly Q3 2026 results
• Positive Sentiment: GLP-1 sales remained the primary catalyst: Mounjaro revenue rose 65% to $10.7 billion and Zepbound generated $5.35 billion, reinforcing Lilly’s leadership in diabetes and obesity treatments. Combined sales exceeded $16 billion. Tirzepatide Q3 sales
• Positive Sentiment: Higher outlook: Lilly raised its 2026 revenue forecast to $91 billion-$92 billion from $85 billion-$87 billion. Expanding Medicare access, middle-income demand and continued obesity-drug adoption supported the improved outlook. Lilly earnings call highlights
• Positive Sentiment: Pipeline momentum improved: Positive Phase 3 results for experimental obesity and diabetes drug retatrutide versus Ozempic strengthened expectations for Lilly’s next generation of metabolic medicines. The FDA also approved additional Mounjaro cardiovascular-risk labeling and once-weekly basal insulin Onswik. Retatrutide trial results
• Positive Sentiment: Analyst support: Royal Bank of Canada raised its price target from $1,500 to $1,600 and maintained an “outperform” rating, signaling confidence that earnings momentum can continue.
• Neutral Sentiment: Lilly’s quarter included roughly $900 million of benefits from Jardiance milestones and favorable rebate and discount adjustments, factors that may not recur.
• Negative Sentiment: Pricing and cost risks remain: Realized prices declined about 15%, with volume growth doing the work of offsetting lower prices. Lilly also recorded approximately $4.2 billion in acquired in-process research-and-development charges, while management acknowledged ongoing pricing pressure. Reuters Lilly outlook report

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.